company background image
603520 logo

Zhejiang Starry PharmaceuticalLtd SHSE:603520 Stock Report

Last Price

CN¥10.19

Market Cap

CN¥4.5b

7D

0.4%

1Y

-40.0%

Updated

14 Jun, 2024

Data

Company Financials +

Zhejiang Starry Pharmaceutical Co.,Ltd.

SHSE:603520 Stock Report

Market Cap: CN¥4.5b

603520 Stock Overview

Engages in the research and development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in China and internationally.

603520 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance2/6
Financial Health2/6
Dividends0/6

Zhejiang Starry Pharmaceutical Co.,Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Zhejiang Starry PharmaceuticalLtd
Historical stock prices
Current Share PriceCN¥10.19
52 Week HighCN¥17.25
52 Week LowCN¥7.86
Beta0.45
1 Month Change-17.82%
3 Month Change-21.01%
1 Year Change-39.99%
3 Year Change-80.25%
5 Year Change-14.39%
Change since IPO59.78%

Recent News & Updates

Shareholders Can Be Confident That Zhejiang Starry PharmaceuticalLtd's (SHSE:603520) Earnings Are High Quality

May 06
Shareholders Can Be Confident That Zhejiang Starry PharmaceuticalLtd's (SHSE:603520) Earnings Are High Quality

Market Might Still Lack Some Conviction On Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Even After 31% Share Price Boost

Mar 12
Market Might Still Lack Some Conviction On Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Even After 31% Share Price Boost

Recent updates

Shareholders Can Be Confident That Zhejiang Starry PharmaceuticalLtd's (SHSE:603520) Earnings Are High Quality

May 06
Shareholders Can Be Confident That Zhejiang Starry PharmaceuticalLtd's (SHSE:603520) Earnings Are High Quality

Market Might Still Lack Some Conviction On Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Even After 31% Share Price Boost

Mar 12
Market Might Still Lack Some Conviction On Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Even After 31% Share Price Boost

Is Zhejiang Starry PharmaceuticalLtd (SHSE:603520) Using Too Much Debt?

Feb 28
Is Zhejiang Starry PharmaceuticalLtd (SHSE:603520) Using Too Much Debt?

Shareholder Returns

603520CN PharmaceuticalsCN Market
7D0.4%-1.1%0.06%
1Y-40.0%-12.5%-16.1%

Return vs Industry: 603520 underperformed the CN Pharmaceuticals industry which returned -11.9% over the past year.

Return vs Market: 603520 underperformed the CN Market which returned -15.5% over the past year.

Price Volatility

Is 603520's price volatile compared to industry and market?
603520 volatility
603520 Average Weekly Movement5.4%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement6.7%
10% most volatile stocks in CN Market10.2%
10% least volatile stocks in CN Market4.2%

Stable Share Price: 603520's share price has been volatile over the past 3 months.

Volatility Over Time: 603520's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19971,845Weiyi Shenwww.starrypharm.com

Zhejiang Starry Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in China and internationally. Its contrast agent products include iohexol, iohexol hydrolysate, iohexol iodide, ioversol, iopamidol, iomeprol, iopromide, cybeclamine, iodixanol, gadopentetic acid dimeglumine, and glutamate; and fluoroquinolones products, such as levofloxacin, levofloxacin hydrochloride, levoflurane, levofluorocarboxylic acid, pazufloxacin, and pazufloxacin mesylate.

Zhejiang Starry Pharmaceutical Co.,Ltd. Fundamentals Summary

How do Zhejiang Starry PharmaceuticalLtd's earnings and revenue compare to its market cap?
603520 fundamental statistics
Market capCN¥4.47b
Earnings (TTM)CN¥46.95m
Revenue (TTM)CN¥2.27b

95.2x

P/E Ratio

2.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
603520 income statement (TTM)
RevenueCN¥2.27b
Cost of RevenueCN¥1.74b
Gross ProfitCN¥534.34m
Other ExpensesCN¥487.39m
EarningsCN¥46.95m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.11
Gross Margin23.51%
Net Profit Margin2.07%
Debt/Equity Ratio176.0%

How did 603520 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.